

## Evonik starts construction of second methionine complex in Singapore

- DL-methionine in continued demand for animal nutrition
- Investment of more than half a billion euros
- Doubling the production capacity in Singapore to 300,000 metric tons per year

Essen/Singapore. Evonik Industries plans to build a second world-scale plant for the production of the amino acid DL-methionine in Singapore are fully on schedule. The company marked the official start of construction with a symbolic ground-breaking ceremony today, officiated by Tharman Shanmugaratnam, Singapore Deputy Prime Minister & Coordinating Minister for Economic and Social Policies. The complex will have an annual production capacity of 150,000 metric tons and is expected to become operational in 2019, with investment costs of more than half a billion euros. Evonik sells DL-methionine under the brand name MetAMINO®.

“Our methionine complex, which came on-stream in late 2014 on Jurong Island, is a success story. This led to our decision to build a second plant next to it,” said Klaus Engel, the chairman of the Executive Board of Evonik Industries, in Singapore today. “The demand for MetAMINO® for animal nutrition is continuing to grow at a very fast rate in Asia.” The new plant will not only produce methionine, but also all strategically important precursors to guarantee product quality and supply security.

“Singapore has proven an ideal location for supplying our Asian customers,” said Reiner Beste, chairman of the Board of Management of Evonik Nutrition & Care GmbH. The new complex will create more than 150 jobs at the location. “We are pleased to have such qualified personnel available to us in this country,” Beste continued.

The new production complex will increase Evonik’s annual capacity of MetAMINO® to a total of approximately 300,000 metric tons in Asia, and to approximately 730,000 metric tons worldwide. The specialty chemicals company produces the amino acid in its world-scale plants in Antwerp (Belgium), Wesseling/Cologne (Germany), Mobile (Alabama, USA), and Singapore.

October 20, 2016

### Scarlett Shi

Communications

Tel +86 21 6119-1200

Fax +86 21 6119-1116

scarlett.shi@evonik.com

### Evonik Industries AG

Rellinghauser Straße 1-11

45128 Essen

Germany

Phone +49 201 177-01

Fax +49 201 177-3475

www.evonik.com

### Supervisory Board

Dr. Werner Müller, Chairman

### Executive Board

Dr. Klaus Engel, Chairman

Christian Kullmann, Deputy Chairman

Dr. Ralph Sven Kaufmann

Thomas Wessel

Ute Wolf

Registered office Essen

Registered court

Essen local court

Commercial Registry B 19474

VAT ID no. DE 811160003

DL-methionine is an essential amino acid, which must be absorbed through feed intake. As a feed additive, it contributes to the efficient, healthy and environmentally friendly nutrition of livestock, particularly poultry and swine. That makes it an important component of ensuring a sustainable animal protein supply for the world's growing population.

Evonik has over 60 years of experience in the manufacture of essential amino acids and provides solutions for efficient and sustainable animal nutrition to customers in over one hundred countries. Evonik wants to make an even greater contribution to the efficiency of animal feed by supplementing its portfolio with innovative feed additives beyond amino acids in order to create additional value for its customers. Evonik's products and services in the area of animal nutrition play a key role worldwide in the production of healthy and affordable food, while preserving natural resources and reducing the ecological footprint.



**Caption:**

Groundbreaking ceremony of Evonik's Second Methionine Complex in Singapore (from left to right):

- Peter Meinshausen, Regional President of Evonik South East Asia, Australia & New Zealand
- Dr. Werner Mueller, Chairman of the Supervisory Board, Evonik Industries AG
- Dr. Beh Swan Gin, Chairman of the Singapore Economic Development Board
- Mr Christian Kullmann, Deputy Chairman of the Executive Board, Evonik Industries AG
- Mr Tharman Shanmugaratnam Deputy Prime Minister and Coordinating Minister for Economic and Social Policies
- Dr. Klaus Engel, Chairman of the Executive Board of Evonik Industries AG
- His Excellency Dr. Michael Witter, Ambassador of the Federal Republic of Germany to Singapore
- Dr. Ralph Sven Kaufmann, Chief Operating Officer, Evonik Industries AG
- Dr. Reiner Beste, Chairman of the Board, Management of Evonik Nutrition & Care GmbH
- Dr. Franck Furno, Project Director Evonik Me6, Evonik Nutrition & Care GmbH

**Company information**

Evonik, the creative industrial group from Germany, is one of the world leaders in specialty chemicals. Profitable growth and a sustained increase in the value of the company form the heart of Evonik's corporate strategy. Its activities focus on the key megatrends health, nutrition, resource efficiency and globalization. Evonik benefits specifically from its innovative prowess and integrated technology platforms. Evonik is active in over 100 countries around the world. In fiscal 2015 more than 33,500 employees generated sales of around €13.5 billion and an operating profit (adjusted EBITDA) of about €2.47 billion.

Evonik Industries has been producing specialty chemical products in the Greater China region (Mainland China, Hong Kong and Taiwan) since the late 1970's; with wide-ranging trading relations already in place prior to this in the region. Evonik regards Greater China as one of the driving forces of the global economy and we consequently endeavor to grow our business in the region. The company now has around 3,000 employees in the Greater China region, the regional sales reached over €1.3 billion in 2015.

**Disclaimer**

In so far as forecasts or expectations are expressed in this press release or where our statements concern the future, these forecasts, expectations or statements may involve known or unknown risks and uncertainties. Actual results or

developments may vary, depending on changes in the operating environment. Neither Evonik Industries AG nor its group companies assume an obligation to update the forecasts, expectations or statements contained in this release.